The GH axis has been central to body composition research for decades. What changed with tesamorelin is precision: instead of exogenous GH flooding the system with a supraphysiological pulse, investigators can use a GHRH analog — tesamorelin — to amplify the body's own somatotroph signalling pattern and study the downstream IGF-1 response in a more translatable model. Stack that on top of progressive mechanical loading and you get one of the more interesting research angles in modern peptide science. This post unpacks the published evidence, explains the mechanism, and tells researchers in Dubai and across the UAE exactly how to buy tesamorelin UAE with the cold chain intact.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Vials are in stock now: tesamorelin 5mg and tesamorelin 10mg, the only two strengths referenced in the clinical trial literature.
Tesamorelin is a synthetic 44-amino-acid analog of endogenous human GHRH (growth hormone-releasing hormone), modified at the N-terminus with a trans-3-hexenoyl group. This single modification does two things: it slows degradation by dipeptidyl peptidase-IV (DPP-IV), extending the half-life, and it preserves the full receptor-binding conformation of the native molecule. The result is a compound that binds GHRH-R on anterior pituitary somatotrophs and drives pulsatile GH secretion — not a flat, constant elevation, but the physiological pulse pattern that downstream tissues respond to most efficiently.
Once GH is released, the liver is the primary site of IGF-1 synthesis. IGF-1 (insulin-like growth factor 1) then acts on skeletal muscle via the IGF-1 receptor to activate PI3K/Akt/mTOR signalling — the canonical anabolic pathway that drives muscle protein synthesis (MPS). In the resistance training research model, investigators are interested in whether pharmacologically amplifying IGF-1 above baseline enhances the anabolic response to mechanical loading, accelerates satellite cell recruitment, or improves the ratio of lean mass gain to visceral fat loss in a simultaneous body recomposition paradigm.
This is the core hypothesis of the tesamorelin + resistance training stack: mechanical loading provides the anabolic stimulus; tesamorelin provides the endocrine amplifier. The published data, reviewed below, does not yet close that loop in a dedicated resistance training cohort — but the IGF-1 and lean mass signals from existing trials are strong enough to motivate serious research interest.
There are four peer-reviewed trials forming the evidence backbone for tesamorelin research. All used the same core methodology: randomized, double-blind, placebo-controlled design; tesamorelin 2mg/day subcutaneous; primary endpoints including visceral adipose tissue (VAT) by CT scan and IGF-1 by serum assay. The body composition data from these trials is what makes tesamorelin relevant to the resistance training research stack.
The landmark Falutz 2007 NEJM trial enrolled 412 subjects with HIV-associated lipodystrophy and randomized them 1:1 to tesamorelin 2mg/day or placebo for 26 weeks. The primary findings are now well-established in the research community:
For investigators studying tesamorelin in resistance training models, the IGF-1 signal is the key data point: a ~50% rise in circulating IGF-1 at 2mg/day represents a substantial endocrine shift that, in the presence of mechanical loading, investigators hypothesize would synergize with exercise-driven mTOR activation to enhance MPS rates.
The 2010 Falutz extension study followed subjects from the original NEJM trial for an additional 26 weeks (52 weeks total). The extension confirmed that the VAT reduction achieved at 26 weeks was sustained with continued tesamorelin use, and that IGF-1 remained elevated above baseline throughout the treatment period. Critically for the research community, subjects who discontinued tesamorelin showed VAT rebound toward baseline — consistent with the compound's mechanism as an amplifier of endogenous GH, not a permanent structural change. This suggests the IGF-1 elevation is dependent on continued GHRH-R stimulation, a pharmacokinetic consideration investigators must account for when designing research protocols.
| Trial | N | Duration | Dose | VAT Change | IGF-1 Change |
|---|---|---|---|---|---|
| Falutz 2007 (NEJM) | 412 | 26 weeks | 2mg/day | −15 to −18% vs. placebo | +~50% vs. baseline |
| Falutz 2010 (JCEM extension) | Subset of above | 52 weeks total | 2mg/day | Sustained through wk 52 | Elevated throughout |
| Stanley 2014 (JAMA) | HIV NAFLD cohort | 12 months | 2mg/day | N/A (liver fat primary) | Elevated in treatment arm |
| Stanley 2019 (Lancet HIV) | Multicentre RCT | 12 months | 2mg/day | N/A (liver fat primary) | Elevated in treatment arm |
Stanley and colleagues at Massachusetts General Hospital extended the tesamorelin evidence base into hepatic fat metabolism. The 2014 JAMA trial demonstrated that tesamorelin 2mg/day reduced liver fat by 32% relative to placebo over 12 months in HIV-positive subjects with non-alcoholic fatty liver disease (NAFLD). The 2019 Lancet HIV multicentre replication confirmed this hepatic fat reduction with strong statistical consistency. The liver fat data is relevant to the resistance training research context for a less obvious reason: hepatic steatosis impairs IGF-1 bioavailability by disrupting the liver's GH-signalling capacity. Investigators working on tesamorelin + resistance training stacks note that concurrent reduction of liver fat may improve the efficiency of the GHRH → IGF-1 conversion, making the hormonal environment more responsive to anabolic stimuli from mechanical loading.
Resistance training induces acute and chronic adaptations in the GH axis. A single bout of heavy resistance exercise elevates GH transiently; chronic training upregulates IGF-1 receptor expression in skeletal muscle. Investigators studying tesamorelin as a GHRH analog in this context are probing a straightforward hypothesis: if tesamorelin elevates circulating IGF-1 by ~50% at steady state (Falutz 2007), and resistance training upregulates IGF-1R sensitivity in muscle, does the combination produce a supra-additive anabolic signal?
IGF-1 binds IGF-1R on skeletal muscle cells, triggering autophosphorylation of the receptor and activation of the IRS-1/PI3K/Akt cascade. Akt then phosphorylates and activates mTORC1, which phosphorylates S6K1 and 4E-BP1 — the rate-limiting regulators of ribosomal translation initiation. The net result is accelerated muscle protein synthesis. Concurrently, Akt phosphorylates FOXO transcription factors, sequestering them in the cytoplasm and suppressing the transcription of muscle atrophy genes (MuRF1, MAFbx/atrogin-1). The dual effect — stimulate synthesis, suppress breakdown — is why IGF-1 is a key focus in lean mass research.
REVIVE LAB UAE stocks tesamorelin in the two vial sizes that align with published research protocols. Investigators should not use unstocked strengths — published data is specific to 2mg/day (the Falutz and Stanley standard) and exploratory 1mg/day arms studied in some models. The table below maps published dosing to REVIVE LAB UAE vial options.
| Vial Size | BAC Water | Concentration | Volume for 2mg Research Dose | Days Per Vial (2mg/day) |
|---|---|---|---|---|
| Tesamorelin 5mg | 1 mL | 5 mg/mL | 0.4 mL | 2.5 days |
| Tesamorelin 5mg | 2 mL | 2.5 mg/mL | 0.8 mL | 2.5 days |
| Tesamorelin 10mg | 2 mL | 5 mg/mL | 0.4 mL | 5 days |
| Tesamorelin 10mg | 4 mL | 2.5 mg/mL | 0.8 mL | 5 days |
Research-context dosing in the Falutz and Stanley trials was consistently 2mg/day SC. The 1mg/day dose has been referenced in exploratory IGF-1 dose-response work and is achievable with both vial sizes. All dosing references are from published investigational protocols — this is not a clinical recommendation.
The Falutz and Stanley trials were not designed to study resistance training. Their primary endpoints were visceral fat (Falutz) and liver fat (Stanley). But the secondary body composition data embedded in these trials is directly relevant to investigators designing exercise-plus-peptide research protocols.
In the Falutz 2007 NEJM data, trunk lean mass was measured as a secondary outcome. The tesamorelin arm showed preservation of lean mass alongside VAT reduction — a meaningful finding because fat loss interventions frequently produce concurrent lean mass loss, and the tesamorelin arm appeared to spare lean tissue. The 26-week extension (Falutz 2010) showed this lean mass preservation effect was sustained at 52 weeks. For investigators, this suggests tesamorelin's IGF-1-mediated anabolic signalling may partially offset the lean mass costs typical of aggressive caloric restriction, a hypothesis directly testable in a resistance training + tesamorelin protocol.
The visceral fat reduction documented by Falutz et al. (15-18% relative to placebo) matters for resistance training research beyond aesthetics. Visceral adipose tissue is metabolically active: it generates free fatty acids that impair insulin signalling, and it secretes adipokines (resistin, TNF-alpha, IL-6) that inhibit the insulin/IGF-1 receptor pathway at the post-receptor level. Reducing VAT by 15-18% while simultaneously elevating IGF-1 by ~50% creates a permissive anabolic environment — the endocrine context in which investigators hypothesize resistance training responses would be maximally robust.
Stanley et al. 2014 (JAMA) demonstrated a 32% reduction in liver fat with tesamorelin 2mg/day over 12 months, confirmed in the 2019 Lancet HIV multicentre replication. Liver fat accumulation blunts GH receptor signalling in hepatocytes — a phenomenon called GH resistance — which in turn reduces hepatic IGF-1 production per unit of GH stimulation. Reducing liver fat with tesamorelin may therefore increase the IGF-1 yield per GHRH pulse, creating a positive feedback loop for investigators studying the GH axis in metabolic disease research models that co-occur with resistance training interventions.
Peptide quality is non-negotiable in research settings. Impure or degraded tesamorelin produces unreliable IGF-1 responses that invalidate downstream data interpretation. REVIVE LAB UAE supplies tesamorelin UAE with HPLC-verified purity, lot-matched COA documentation, and cold-chain dispatch. Every vial — whether tesamorelin 5mg or 10mg — is dispatched at 2-8°C in validated insulated packaging. This is the supply standard used in the Stanley and Falutz trial supply chains. If you are searching for buy tesamorelin UAE, tesamorelin Dubai 24h delivery, or tesamorelin in stock UAE, REVIVE LAB UAE is the only peptides UAE supplier that meets these verification requirements across all seven emirates.
| Emirate / City | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, DIFC, Downtown, Business Bay, JVC, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes — 2-8°C validated |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes — 2-8°C validated |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes — 2-8°C validated |
| Ajman | Next-day, 18-24 hours | Yes | Yes — 2-8°C validated |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes — 2-8°C validated |
| Fujairah | Next-day, 24 hours | Yes | Yes — 2-8°C validated |
| Umm Al Quwain | Next-day, 18-24 hours | Yes | Yes — 2-8°C validated |
| Al Ain | Next-day, 24 hours | Yes | Yes — 2-8°C validated |
Researchers ordering tesamorelin same day Dubai before the daily dispatch cut-off receive cold-pack vials within 4-8 hours across Dubai Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah, Jumeirah, Emirates Hills and Arabian Ranches. For other emirates, the tesamorelin 24h delivery window applies. Cash on delivery Dubai and all seven emirates is the standard — no advance payment required.
REVIVE LAB UAE stocks tesamorelin in 5mg and 10mg lyophilized vials only — the same vial strengths referenced across the Falutz 2007 (NEJM), Falutz 2010 (JCEM), Stanley 2014 (JAMA), and Stanley 2019 (Lancet HIV) trial supply chains. Research-context dosing in published literature is 1-2mg/day SC. No other vial strengths are stocked. All vials carry HPLC-verified purity documentation and lot-matched COA.
Yes. REVIVE LAB UAE offers tesamorelin same day Dubai dispatch for orders placed before the daily cut-off, with 4-8 hour delivery to all major Dubai districts including Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah and Jumeirah. Tesamorelin Dubai 24h delivery applies to same-day dispatch with next-day arrival for Abu Dhabi, Sharjah, RAK, Fujairah, Al Ain and other emirates. Cash on delivery is available. All vials are cold-chain dispatched at 2-8°C in insulated packaging.
Published investigators used 2mg/day subcutaneous tesamorelin in the core Falutz and Stanley trials, which produced the documented ~50% IGF-1 elevation and 15-18% VAT reduction. A 1mg/day exploratory dose has also been referenced in dose-response research contexts. Both doses are achievable with REVIVE LAB UAE's tesamorelin 5mg and 10mg vials. All dosing references are from published peer-reviewed protocols and are not clinical recommendations. All use is strictly research-context only.